Adeno-associated virus (AAV) has been studied extensively as a gene therapy vector. Results from both preclinical studies and clinical trials using recombinant AAV (rAAV) vector suggest that this vector would be safe and effective for muscle gene delivery. Currently, the most widely used rAAV vector is based on AAV serotype 2 because it is the most extensively characterized serotype. Recently, characterization of AAV serotype 1 demonstrated that AAV1 based vectors are approximately 10 to 20-fold more effective than AAV2 for delivery into muscle. Such dramatic differences suggest that AAV1 vector is not merely an alternative vector for AAV2 but has distinctive advantages over the AAV2 vector. Scientifically, AAV1 offers an excellent tool to study the biology and vectorology of AAV. As a continuation of my previous work, the following studies are proposed to characterize AAV1 as a gene therapy vector using hemophilia B as a disease model. 1). To identify the tissue tropism determinants of AAV1 for muscle. The hypothesis to be tested in this specific aim is that some dissimilar amino acid clusters between AAV1 and AAV2 account for the differences in affinity for muscle. Such dramatic differences in transducing muscle provide a reliable assay for the tissue tropism determinants. 2). To characterize the biological properties of AAV1/2 hybrid helpers, and to identify the cellular receptors for AAV1 virus. 3). To explore the effectiveness of AAV 1 and its hybrid derivative vectors in correcting the phenotype in hemophilic mice, and to administer these vectors to animals with neutralizing antibodies against AAV.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL069051-03
Application #
6684156
Study Section
Medical Biochemistry Study Section (MEDB)
Program Officer
Link, Rebecca P
Project Start
2001-12-01
Project End
2005-11-30
Budget Start
2003-12-01
Budget End
2004-11-30
Support Year
3
Fiscal Year
2004
Total Cost
$340,000
Indirect Cost
Name
Children's Hospital of Philadelphia
Department
Type
DUNS #
073757627
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Xiao, Weidong; Gao, Guangping; Ling, Chen et al. (2018) Impact of neutralizing antibodies against AAV is a key consideration in gene transfer to nonhuman primates. Nat Med 24:699
Wang, Qizhao; Wu, Zhongren; Zhang, Junping et al. (2017) A Robust System for Production of Superabundant VP1 Recombinant AAV Vectors. Mol Ther Methods Clin Dev 7:146-156
Lu, Hui; Chen, Lingxia; Wang, Jinhui et al. (2008) Complete correction of hemophilia A with adeno-associated viral vectors containing a full-size expression cassette. Hum Gene Ther 19:648-54
Chen, Lingxia; Zhu, Fuxiang; Li, Juan et al. (2007) The enhancing effects of the light chain on heavy chain secretion in split delivery of factor VIII gene. Mol Ther 15:1856-62
Hauck, Bernd; Xu, Ray Ruian; Xie, Jing et al. (2006) Efficient AAV1-AAV2 hybrid vector for gene therapy of hemophilia. Hum Gene Ther 17:46-54
Hauck, Bernd; Zhao, Wei; High, Katherine et al. (2004) Intracellular viral processing, not single-stranded DNA accumulation, is crucial for recombinant adeno-associated virus transduction. J Virol 78:13678-86
Hauck, Bernd; Xiao, Weidong (2003) Characterization of tissue tropism determinants of adeno-associated virus type 1. J Virol 77:2768-74
Hauck, Bernd; Chen, Ling; Xiao, Weidong (2003) Generation and characterization of chimeric recombinant AAV vectors. Mol Ther 7:419-25
Mingozzi, Federico; Schuttrumpf, Jorg; Arruda, Valder R et al. (2002) Improved hepatic gene transfer by using an adeno-associated virus serotype 5 vector. J Virol 76:10497-502
Cao, L; During, M; Xiao, W (2002) Replication competent helper functions for recombinant AAV vector generation. Gene Ther 9:1199-206